More NOTCH3 positivity was observed in high-grade tumours and was associated with a higher risk of mortality, thus indicating NOTCH3 as a potential reliable IHC marker for selecting BCa patients who may require more intensive follow-up. This evidence concerns the gene NOTCH3 and neoplasm.